Carl Icahn’s Icahn Enterprises through its subsidiary IEH Biopharma LLC unveiled a tender offer on Wednesday to buy up all of Vivus’ convertible notes at a price of $680 for each $1,000 note. Reacting favorably to the announcement, obesity company Vivus shares jumped 13% to $1.35 on Wednesday. Icahn into biopharma again IEH Biopharma LLC, a subsidiary of Icahn Enterprises L.P., announced on Wednesday a cash tender offer for any and all of the outstanding 4.50% Convertible Senior Notes due 2020 of struggling obesity drugmaker Vivus, Inc. at a price of $680 for each $1,000 of principal amount of the…
Icahn Unveils Tender Offer For Vivus' Debt
Mani
Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports